ASXL1 Frameshift Mutations Drive Inferior Outcomes in CMML Without Negative Impact in MDS

Clinical Lymphoma, Myeloma and Leukemia- United States

doi 10.1016/j.clml.2016.07.122

Full Text

Abstract

Available in

Date

Authors

Publisher

Elsevier BV

Related search

Mutations of ASXL1 Gene in Myeloproliferative Neoplasms

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2009English

Prolonged Responses in Patients With MDS and CMML Treated With Azacitidine and Etanercept

British Journal of Haematology
Hematology
2010English

ASXL1 Mutations in Chinese Patients With Essential Thrombocythemia

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2018English

A Benign Course of MDS With Del 7q and ASXL1 Mutation

Hematology & Transfusion International Journal
2018English

Methyl-Directed Repair of Frameshift Mutations in Heteroduplex DNA.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1986English

Prognostic Interaction Between ASXL1 and TET2 Mutations in Chronic Myelomonocytic Leukemia

Blood Cancer Journal
OncologyHematology
2016English

Prognostic Impact of Variant Allelic Frequency of Molecular Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) on Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes

Biology of Blood and Marrow Transplantation
TransplantationHematology
2017English

Pathological ASXL1 Mutations and Protein Variants Impair Neural Crest Development

Stem Cell Reports
BiochemistryGeneticsDevelopmental BiologyCell Biology
2019English

Frameshift Suppressor Mutations Outside the Anticodon in Yeast Proline tRNAs Containing an Intervening Sequence.

Molecular and Cellular Biology
Cell BiologyMolecular Biology
1985English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy